|
|
Blood, 1 September 2006, Vol. 108, No. 5, pp. 1724-1732.
Prepublished online as a Blood First Edition Paper on May 16, 2006; DOI 10.1182/blood-2006-03-009910.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation
Ichiro Hanamura,
James P. Stewart,
Yongsheng Huang,
Fenghuang Zhan,
Madhumita Santra,
Jeffrey R. Sawyer,
Klaus Hollmig,
Maurizio Zangarri,
Mauricio Pineda-Roman,
Frits van Rhee,
Federica Cavallo,
Bart Burington,
John Crowley,
Guido Tricot,
Bart Barlogie, and
John D. Shaughnessy, Jr
From the Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock; and Cancer Research and Biostatistics, Seattle, WA.
Using fluorescence in situ hybridization we investigated amplification of chromosome band 1q21 (Amp1q21) in more than 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS; n = 14), smoldering multiple myeloma (SMM; n = 31), and newly diagnosed MM (n = 479) as well as 45 with relapsed MM. The frequency of Amp1q21 was 0% in MGUS, 45% in SMM, 43% in newly diagnosed MM, and 72% in relapsed MM (newly diagnosed versus relapsed MM, P < .001). Amp1q21 was detected in 10 of 12 patients whose disease evolved to active MM compared with 4 of 19 who remained with SMM (P < .001). Patients with newly diagnosed MM with Amp1q21 had inferior 5-year event-free/overall survival compared with those lacking Amp1q21 (38%/52% versus 62%/78%, both P < .001). Thalidomide improved 5-year EFS in patients lacking Amp1q21 but not in those with Amp1q21 (P = .004). Multivariate analysis including other major predictors revealed that Amp1q21 was an independent poor prognostic factor. Relapsed patients who had Amp1q21 at relapse had inferior 5-year postrelapse survival compared with those lacking Amp1q21 at relapse (15% versus 53%, P = .027). The proportion of cells with Amp1q21 and the copy number of 1q21 tended to increase at relapse compared with diagnosis. Our data suggest that Amp1q21 is associated with both disease progression and poor prognosis.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Gain of 1q21 in multiple myeloma: from bad to worse?
- Pieter Sonneveld
Blood 2006 108: 1426-1427.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. Blotta, P. Tassone, R. H. Prabhala, P. Tagliaferri, D. Cervi, S. Amin, J. Jakubikova, Y.-T. Tai, K. Podar, C. S. Mitsiades, et al.
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance
Blood,
October 8, 2009;
114(15):
3276 - 3284.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Avet-Loiseau, C. Li, F. Magrangeas, W. Gouraud, C. Charbonnel, J.-L. Harousseau, M. Attal, G. Marit, C. Mathiot, T. Facon, et al.
Prognostic Significance of Copy-Number Alterations in Multiple Myeloma
J. Clin. Oncol.,
September 20, 2009;
27(27):
4585 - 4590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Chiecchio, G. P. Dagrada, R. K.M. Protheroe, D. M. Stockley, A. G. Smith, K. H. Orchard, N. C.P. Cross, C. J. Harrison, F. M. Ross, and on behalf of the UK Myeloma Forum
Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case
Haematologica,
July 1, 2009;
94(7):
1024 - 1028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hose, T. Reme, T. Meissner, J. Moreaux, A. Seckinger, J. Lewis, V. Benes, A. Benner, M. Hundemer, T. Hielscher, et al.
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma
Blood,
April 30, 2009;
113(18):
4331 - 4340.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Spanoudakis, M. Hu, K. Naresh, E. Terpos, V. Melo, A. Reid, I. Kotsianidis, S. Abdalla, A. Rahemtulla, and A. Karadimitris
Regulation of multiple myeloma survival and progression by CD1d
Blood,
March 12, 2009;
113(11):
2498 - 2507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Xiong, X. Wu, S. Starnes, S. K. Johnson, J. Haessler, S. Wang, L. Chen, B. Barlogie, J. D. Shaughnessy Jr, and F. Zhan
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma
Blood,
November 15, 2008;
112(10):
4235 - 4246.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Bochtler, U. Hegenbart, F. W. Cremer, C. Heiss, A. Benner, D. Hose, M. Moos, J. Bila, C. R. Bartram, A. D. Ho, et al.
Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability
Blood,
May 1, 2008;
111(9):
4700 - 4705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Tian, T. H. Landowski, O. W. Stephens, S. Yaccoby, B. Barlogie, and J. D. Shaughnessy Jr.
Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma
Mol. Cancer Ther.,
March 1, 2008;
7(3):
500 - 509.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mahtouk, D. Hose, J. De Vos, J. Moreaux, M. Jourdan, J. F. Rossi, T. Reme, H. Goldschmidt, and B. Klein
Input of DNA Microarrays to Identify Novel Mechanisms in Multiple Myeloma Biology and Therapeutic Applications
Clin. Cancer Res.,
December 15, 2007;
13(24):
7289 - 7295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. K. Prasad, F. Zhan, J. Shaughnessy, D. Focosi, A. T. Andrews, R. A. Kyle, and S. V. Rajkumar
Smoldering Multiple Myeloma
N. Engl. J. Med.,
September 6, 2007;
357(10):
1048 - 1050.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Katzel, P. Hari, and D. H. Vesole
Multiple Myeloma: Charging Toward a Bright Future
CA Cancer J Clin,
September 1, 2007;
57(5):
301 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Sonneveld, B. van der Holt, C. M. Segeren, E. Vellenga, A. J. Croockewit, G. E.G. Verhoef, J. J. Cornelissen, M. R. Schaafsma, M. H.J. van Oers, P. W. Wijermans, et al.
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial
Haematologica,
July 1, 2007;
92(7):
928 - 935.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zhan, S. Colla, X. Wu, B. Chen, J. P. Stewart, W. M. Kuehl, B. Barlogie, and J. D. Shaughnessy Jr
CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms
Blood,
June 1, 2007;
109(11):
4995 - 5001.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zhan, B. Barlogie, V. Arzoumanian, Y. Huang, D. R. Williams, K. Hollmig, M. Pineda-Roman, G. Tricot, F. van Rhee, M. Zangari, et al.
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
Blood,
February 15, 2007;
109(4):
1692 - 1700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zhan, Y. Huang, S. Colla, J. P. Stewart, I. Hanamura, S. Gupta, J. Epstein, S. Yaccoby, J. Sawyer, B. Burington, et al.
The molecular classification of multiple myeloma
Blood,
September 15, 2006;
108(6):
2020 - 2028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
